Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 64.2% in February

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 17,100 shares, a decline of 64.2% from the January 31st total of 47,700 shares. Based on an average daily trading volume, of 506,700 shares, the short-interest ratio is presently 0.0 days. Approximately 0.2% of the company’s shares are short sold.

Sol-Gel Technologies Stock Performance

Shares of NASDAQ SLGL opened at $0.56 on Friday. Sol-Gel Technologies has a fifty-two week low of $0.33 and a fifty-two week high of $1.65. The company has a market cap of $15.46 million, a price-to-earnings ratio of -1.63 and a beta of 1.31. The business’s 50 day moving average price is $0.87 and its 200-day moving average price is $0.69.

Hedge Funds Weigh In On Sol-Gel Technologies

A hedge fund recently bought a new stake in Sol-Gel Technologies stock. Raymond James Financial Inc. bought a new stake in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 108,990 shares of the company’s stock, valued at approximately $101,000. Raymond James Financial Inc. owned 0.39% of Sol-Gel Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 26.18% of the company’s stock.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.